hsa-mir-6825: Among the identified genes in the present study, LINC02683, AC244517.5, LINC02418, LINC01322, AC011468.3, and hsa-mir-6825 were identified as risk factors [PMC8236863]. Patients with high expression of hsa-mir-6825 had a lower recurrence-free survival compared to those with low expression [PMC8236863]. The study also reported the identification of LINC02683, AC244517.5, LINC02418, LINC01322, AC011468.3, AC020637.1, and AC027117.2 for the first time in lung squamous cell carcinoma (LUSC) [PMC8236863]. In mice, hsa-mir-6825 was shown to increase LDLR mRNA expression by reducing PCSK9/SREBP2 interaction [PMC9263516]. Hsa-mir-6825 mimic and inhibitor were used in experiments conducted on HL-1 cardiomyocyte cells to determine its expression and its role in PCSK9 regulation [PMC8389247]. Pterostilbene was found to suppress PCSK9 epigenetically through hsa-mir-6825 mediated downregulation of SREBP2, leading to increased LDLR mRNA expression [PMC8389247]. Pterostilbene also reduced PCSK9/SREBP2 interaction and mRNA expression by increasing the expression of hsa-mir-6825, thereby increasing LDLR mRNA expression [PMC8389247].